All In Biotech

Drug Trial Radar · NCT04514653

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

A Phase 2, Randomized, Dose-escalation, Ranibizumab-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered Via One or Two Suprachoroidal Space (SCS) Injections in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 146 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

146

Actual

Start

Aug 25, 2020

Primary completion

Oct 13, 2026

Study completion Feb 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
Collaborators
REGENXBIO Inc.
First posted
Aug 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This interventional study is being conducted with an investigational gene therapy treatment called ABBV-RGX-314 (also known as RGX-314) and is being developed as a potential one-time gene therapy treatment for neovascular (wet) age-related macular degeneration (wet AMD or nAMD). The typical treatment for nAMD is frequent injections of anti-VEGF therapy. Researchers are testing ABBV-RGX-314 to see if it has similar effects as the current approved standard of care, such as Lucentis® or Eylea® injections. The duration of this study will be up to 52 weeks or for ranibizumab control participants who cross over to ABBV-RGX-314 after week 52, up to 80 weeks post-randomization. The primary outcome measure for this investigational study is to evaluate the mean change in best-corrected visual acuity (BCVA) for ABBV-RGX-314 compared with ranibizumab monthly at the Week 40 visit.

Conditions

  • Neovascular Age-Related Macular Degeneration (nAMD)

Interventions

  • RanibizumabBiological

    Ranibizumab (anti-VEGF agent)

  • ABBV-RGX-314 Dose 1Genetic

    AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)

  • ABBV-RGX-314 Dose 2Genetic

    AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)

  • ABBV-RGX-314 Dose 3Genetic

    AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)

  • Local SteroidDrug

    Local steroid

  • Topical SteroidDrug

    Topical steroid

  • ABBV-RGX-314 Dose 4Genetic

    AAV8 vector containing a transgene for anti-VEGF fab (Dose 4)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline in BCVA to Week 40 based on the Early Treatment Diabetic Retinopathy Study (ETDRS) scoreTime frame: 40 weeks

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Retinal Research Institute /ID# 255925

    Phoenix, Arizona

  • California Retina Consultants - Bakersfield /ID# 255910

    Bakersfield, California

  • Retina Vitreous Assoc Med Grp /ID# 255921

    Beverly Hills, California

  • Retinal Diagnostic Center /ID# 272275

    Campbell, California

  • Northern California Retina Vitreous Associates Medical Group, Inc /ID# 255920

    Mountain View, California

  • Retina Consultants of San Diego /ID# 255911

    Poway, California

  • California Retina Consultants - Santa Barbara /ID# 255923

    Santa Barbara, California

  • Southeast Retina Center /ID# 255912

    Augusta, Georgia

  • Springfield Clinic - First /ID# 272274

    Springfield, Illinois

  • Johns Hopkins Hospital /ID# 255919

    Baltimore, Maryland

  • Ophthalmic Consultants of Boston /ID# 255917

    Boston, Massachusetts

  • Sierra Eye Associates /ID# 255908

    Reno, Nevada

  • Eye Associates of New Mexico /ID# 255915

    Albuquerque, New Mexico

  • Duke University Medical Center /ID# 267646

    Durham, North Carolina

  • Mid Atlantic Retina /ID# 255906

    Philadelphia, Pennsylvania

  • Charles Retina Institute /ID# 255922

    Germantown, Tennessee

  • Tennessee Retina - Nashville /ID# 255918

    Nashville, Tennessee

  • Retina Consultants - The Woodlands /ID# 255924

    The Woodlands, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.